Thanks pierre. Your annual expectation of 12 cps lines up with average analyst expectations and from a commercial perspective with risks apparent the interim and final split looks logical to me
https://www.marketscreener.com/quote...44/financials/
12 cps grossed up for imputation credits is 12 / 0.72 = 16.67 cps and on a $2.36 share price that's 7.06% gross yield, growing in the years to come.
Lets get a bit creative here and look at the forward yield investment case for next financial year.
First lets establish the base case. The current SP is $2.36 but if we assume you get 5 cents back in a few weeks there's a good argument for saying the net price looking at this from a FY23 income perspective is this is a net $2.31 investment.
Average analyst forecast for FY23 is 13 cps which grossed up for imputation credits is 13 / 0.72 = 18.06 cps which on a $2.31 net investment per share shows a 7.82 % gross yield + growth in future years. Hmmm
Risks apparent appear to revolve around Covid and its effect on the economy. HGH lend to lots of small business's and I am seeing some of them in deep stress so I would expect their Covid provisioning will be needed in the second half of FY22.